Jazz Pharmaceuticals (JAZZ) Short term Debt (2010 - 2026)

Jazz Pharmaceuticals' Short term Debt history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Short term Debt rose 3224.19% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 3224.19% YoY), while the FY2025 annual figure was $1.0 billion, up 3222.26% from the prior year.
• Short term Debt was $1.0 billion for Q1 2026 at Jazz Pharmaceuticals, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $1.0 billion in Q1 2026 to a low of $31.0 million in Q1 2022.
• Historically, Short term Debt has averaged $401.0 million across 5 years, with a median of $31.0 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Short term Debt slumped 94.88% in 2025, then surged 3224.19% in 2026.
• A 5-year view of Short term Debt shows it stood at $31.0 million in 2022, then surged by 1851.46% to $605.0 million in 2023, then slumped by 94.88% to $31.0 million in 2024, then soared by 3222.26% to $1.0 billion in 2025, then grew by 0.06% to $1.0 billion in 2026.
• The last three Short term Debt figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.